Abstract:A diverse group of RNA viruses have the ability to gain access to the central nervous system (CNS) and cause severe neurological disease. Current treatment for people with this type of infection is generally limited to supportive care. To address the need for reliable antivirals, we utilized a strategy of lethal mutagenesis to limit virus replication. We evaluated ribavirin (RBV), favipiravir (FAV) and N 4 -hydroxycytidine (NHC) against La Crosse virus (LACV), which is one of the most common causes of pediatric arboviral encephalitis cases in North America and serves as a model for viral CNS invasion during acute infection. NHC was approximately 3 to 170 times more potent than RBV or FAV in neuronal cells. Oral administration of molnupiravir (MOV), the prodrug of NHC, decreased neurological disease development (assessed as limb paralysis, ataxia and weakness, repeated seizures, or death) by 31% (4 mice survived out of 13) when treatment was started on the day of infection. MOV also reduced disease by 23% when virus was administered intranasally (IN). NHC and MOV produced less fit viruses by incorporating predominantly G to A or C to U mutations. Furthermore, NHC also inhibited virus production of two other orthobunyaviruses, Jamestown Canyon virus and Cache Valley virus. Collectively, these studies indicate that NHC/MOV has therapeutic potential to inhibit viral replication and subsequent neurological disease caused by orthobunyaviruses and potentially as a generalizable strategy for treating acute viral encephalitis. Mutagenic ribonucleosides can be viewed as broadly acting antivirals against RNA viruses. These viruses have small genomes of essential genes and thus are susceptible to enhanced mutation rates as an antiviral strategy. Here we show that the mutagenic ribonucleoside N 4 -hydroxycytidine (NHC) and its prodrug molnupiravir are active against the negative strand bunyavirus La Crosse Virus. Loss of viral infectivity was proportional to the density of mutations induced by NHC. Using a mouse model, we showed that oral administration of molnupiravir attenuated encephalitis caused by La Crosse virus and resulted in reduced virus titers and less fit virus in the brain. This treatment approach should be widely applicable to acute RNA virus diseases, especially those with high morbidity and an absence of other treatment options.

Two short approaches to the COVID-19 drug beta-D-N4- hydroxycytidine and its prodrug molnupiravir

A path from synthesis to emergency use authorization of molnupiravir as a COVID-19 therapy

Molnupiravir: Mechanism of action, clinical, and translational science

β-d-N4-hydroxycytidine, a metabolite of molnupiravir, exhibits in vitro antiviral activity against rabies virus

Catalytic Regioselective Acylation of Unprotected Nucleosides for Quick Access to COVID and Other Nucleoside Prodrugs

Expedient Synthesis of Antiviral Drug Molnupiravir from D-Ribose and Cytosine

Assessing the mitochondrial safety profile of the molnupiravir active metabolite, β-d-N4-hydroxycytidine (NHC), in the physiologically relevant HepaRG model

Binding Mechanism of the Active Form of Molnupiravir to RdRp of SARS-CoV-2 and Designing Potential Analogues: Insights from Molecular Dynamics Simulations

Comprehensive genotoxicity and carcinogenicity assessment of molnupiravir

New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses

Molnupiravir inhibits human norovirus and rotavirus replication in 3D human intestinal enteroids

Molnupiravir and Nirmatrelvir-Ritonavir: Oral COVID Antiviral Drugs

Development and Validation of a High-Performance Liquid Chromatography with Tandem Mass Spectrometry (HPLC-MS/MS) Method for Quantification of Major Molnupiravir Metabolite (β-D-N4-hydroxycytidine) in Human Plasma

Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19

Experimental and theoretical study on supramolecular encapsulation of molnupiravir by Cucurbit[7]uril: A potential formulating agent for COVID-19

The COVID-19 Oral Drug Molnupiravir Is a CES2 Substrate: Potential Drug-Drug Interactions and Impact of CES2 Genetic Polymorphism In Vitro

The pill of recovery; Molnupiravir for treatment of COVID-19 patients; a systematic review

Identification of Therapeutic Drugs Against COVID-19 Through Computational Investigation on Drug Repurposing and Structural Modification

Molnupiravir, an Oral Antiviral Treatment for COVID-19

Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry

N 4 -Hydroxycytidine/molnupiravir inhibits RNA virus-induced encephalitis by producing less fit mutated viruses